Clinical significance of anti-Ro52 (TRIM21) antibodies in adult patients with connective tissue diseases.

MLA

Decker, Paul, et al. “Clinical Significance of Anti-Ro52 (TRIM21) Antibodies in Adult Patients with Connective Tissue Diseases.” European Journal of Internal Medicine, vol. 91, Sept. 2021, pp. 45–52. EBSCOhost, https://doi.org/10.1016/j.ejim.2021.04.020.

APA

Decker, P., Moulinet, T., Lopez, B., Dubucquoi, S., Bonnotte, B., Lakomy, D., Revuz, S., Luc, A., Bittencourt, M. D. C., Hachulla, E., & Jaussaud, R. (2021). Clinical significance of anti-Ro52 (TRIM21) antibodies in adult patients with connective tissue diseases. European Journal of Internal Medicine, 91, 45–52. https://doi.org/10.1016/j.ejim.2021.04.020

Chicago

Decker, Paul, Thomas Moulinet, Benjamin Lopez, Sylvain Dubucquoi, Bernard Bonnotte, Daniela Lakomy, Sabine Revuz, et al. 2021. “Clinical Significance of Anti-Ro52 (TRIM21) Antibodies in Adult Patients with Connective Tissue Diseases.” European Journal of Internal Medicine 91 (September): 45–52. doi:10.1016/j.ejim.2021.04.020.